Tirofiban is a synthetic platelet glycoprotein IIb/IIIa receptor antagonist used in the treatment of patients with non-ST-segment elevation acute coronary syndromes, or ACSs. It helps reduce thrombosis and is often used in combination with other drugs such as aspirin and clopidogrel. In this blog post, we will look at what tirofiban is and how it works, as well as its benefits for medical professionals. We will also discuss potential side effects and contraindications when considering adding tirofiban to a patient’s treatment plan. With this information, healthcare professionals can make an informed decision on whether or not tirofiban is applicable for their patient.
Tirofiban is a non-peptide, small molecule inhibitor of platelet glycoprotein IIb/IIIa. It is used in combination with aspirin and heparin to treat unstable angina and non-ST segment elevation myocardial infarction. Tirofiban has also been shown to be effective in the treatment of ST segment elevation myocardial infarction when used in combination with aspirin and clopidogrel. The benefits of tirofiban include its ability to rapidly and effectively inhibit platelet aggregation, its high degree of specificity for platelet glycoprotein IIb/IIIa, and its relatively short half-life.
Tirofiban is a direct inhibitor of factor XIa. It works by binding to and inhibiting factor XIa, thereby preventing the activation of factor XII and thrombin generation. This results in a decrease in clotting activity and an increase in bleeding time.
Tirofiban is a highly effective antithrombotic agent that has a wide range of benefits for medical professionals. Tirofiban is a reversible inhibitor of the platelet glycoprotein IIb/IIIa receptor and has demonstrated efficacy in the prevention and treatment of thrombotic events. The most common use of tirofiban is in the perioperative setting to prevent thrombosis and keep blood flowing smoothly through the surgical site. Tirofiban has also been shown to be effective in the treatment of acute myocardial infarction, stroke, and unstable angina. In addition, tirofiban has been shown to be safe and well-tolerated in clinical trials.
Tirofiban is a potent platelet inhibitor and as such, can cause serious bleeding. The most common side effects are oozing from intravenous sites and epistaxis (nose bleeds). Less common side effects include gastrointestinal bleeds, brain bleeds, and hemorrhagic strokes. While the incidence of these more serious side effects is low, they can be life-threatening. Therefore, it is important that patients on tirofiban be closely monitored for any signs or symptoms of bleeding.
Tirofiban is a glycoprotein IIb/IIIa inhibitor used to treat patients with acute coronary syndrome (ACS). It is indicated for use in combination with aspirin and heparin in patients who are undergoing percutaneous coronary intervention (PCI). Tirofiban has been shown to improve outcomes in ACS patients, including reducing the risk of death, myocardial infarction, and stroke.
Tirofiban should be considered for use in all patients with ACS who are undergoing PCI. In addition, tirofiban may be considered for use in high-risk ACS patients who are not undergoing PCI but who are at risk for ischemic events.
Tirofiban is a prescription medication used to treat coronary artery disease. It is an oral medication taken twice daily with or without food. Tirofiban should be taken at the same time each day to maintain an even level of medication in your blood.
There are a few potential drug interactions with tirofiban that medical professionals should be aware of. When taken with other medications that increase the risk of bleeding, there is an increased risk for serious bleeding events with tirofiban. This includes medications such as aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and warfarin. There is also an increased risk for bleeding when tirofiban is taken with certain platelet inhibitors such as clopidogrel. There is a potential for reduced efficacy of tirofiban when taken with CYP3A4 inhibitors such as ketoconazole or grapefruit juice. Finally, tirofiban may increase the levels of certain medications that are metabolized by CYP3A4 such as simvastatin.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
2.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
3.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
4.
According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.
5.
A garden can save your life
1.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care
5.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation